Relationship between peculiarities of atrial fibrillation, body mass index and adipokines levels

Abstract

Aim: To assess the value of body mass index (BMI) and adipokine levels in predicting development of atrial fibrillation (AF) in the general population.

Methods: Three hundred and ninety eight patients were examined for the presence of phenotype metabolically healthy obesity (MHO), according to the Wildman criteria; adipokine levels were assessed by enzyme immunoassay method; AF was assessed by electrocardiography (ECG) and/or by ECG diurnal monitoring.

Results: Obesity (group 1) and overweight (group 2) was present in 23.7% and 42.0% of participants; while 21.1% were normal body weight (group 3) and 13.1% had a BMI < 19.9 kg/m² (group 4). Phenotype MHO was detected in 19.6% patients. At follow-up, 32.4% of participants developed AF. Adiponectin levels were significantly higher in MHO patients as compared to metabolically unhealthy patients with abdominal obesity (AO). High molecular weight adiponectin (HMVAN) levels were significantly decreased in patients of groups 1 and 4, as compared to groups 2 and 3. Correlation between AF and HMWAN was determined by regressive analysis in patients of 1st and 4th groups (β = -0.24, P = 0.003 and β = -0.26, P = 0.002, respectively).

Conclusion: The probability of developing AF increases with AO and decreased BMI, which is accompanied by a change in HMVAN levels. In MHO patients, the probability of AF developing is identical with persons having normal BMI.

Keywords

Atrial fibrillation / obesity / metabolically healthy obesity / metabolically unhealthy obesity / serum leptin / high-molecular-weight adiponectin

References

[1] Ortega FB,Blair SN.Obesity and cardiovascular disease..Circ Res2016;118:1752-70

[2] Asghar O,Hayat SA,Heagerty AM.Obesity, diabetes and atrial fibrillation; epidemiology, mechanisms and interventions..Curr Cardiol Rev2012;8:253-64 PMCID:PMC3492809

[3] Flegal KM,Orpana H.Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis..JAMA2013;309:71-82 PMCID:PMC4855514

[4] Lee H,Lee SH,Rhee TM,Lee SR,Lim WH,Cha MJ.Atrial fibrillation risk in metabolically healthy obesity: a nationwide population-based study..Int J Cardiol2017;240:221-7

[5] Payvar S,Rao SV,Neely M,Daggubati R.In-hospital outcomes of percutaneous coronary interventions in extremely obese and normal-weight patients: findings from the NCDR (National Cardiovascular Data Registry)..J Am Coll Cardiol2013;62:692-6

[6] Wanahita N,Bangalore S,Somers VK.Atrial fibrillation and obesity--results of a meta-analysis..Am Heart J2008;155:310-5

[7] Wang TJ,Levy D,Wolf PA,Benjamin EJ.Obesity and the risk of new-onset atrial fibrillation..JAMA2004;292:2471-7

[8] Guglin M,Chen R.Relation of obesity to recurrence rate and burden of atrial fibrillation..Am J Cardiol2011;107:579-82

[9] Frost L,Vestergaard P.Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish diet, cancer, and health study..Am J Med2005;118:489-95

[10] Murphy NF,Stewart S,Hole D.Long-term cardiovascular consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study)..Eur Heart J2006;27:96-106

[11] Goette A,Röcken C,Geller JC,Ansorge S,Lendeckel U.Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation..J Am Coll Cardiol2000;35:1669-77

[12] Dzeshka MS,Snezhitskiy V.Cardiac fibrosis in patients with atrial fibrillation: mechanisms and clinical implications..J Am Coll Cardiol2015;66:943-59

[13] Nattel S.Atrial remodeling and atrial fibrillation: recent advances and translational perspectives..J Am Coll Cardiol2014;63:2335-45

[14] Ito K,Kawai M,Narui R,Tanigawa S,Tokuda M,Matsuo S,Yoshimura M.Morphological change of left atrium in obese individuals..Int J Cardiol2011;152:117-9

[15] Munger TM,Masaki M,Mankad SV,Asirvatham SJ,Lee HC,Hodge DO,Buescher TL,Ma C,Chen PS,Cha YM.Electrophysiological and hemodynamic characteristics associated with obesity in patients with atrial fibrillation..J Am Coll Cardiol2012;60:851-60

[16] Ouchi N,Lugus JJ.Adipokines in inflammation and metabolic disease..Nat Rev Immunol2011;11:85-97 PMCID:PMC3518031

[17] Van de Voorde J,Boydens C.Adipocytokines in relation to cardiovascular disease..Metabolism2013;62:1513-21

[18] Wildman RP,Reynolds K,Rajpathak S,Sowers MR.The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004)..Arch Intern Med2008;168:1617-24

[19] Macheret F,Djousse L,Mukamal KJ,Siscovick DS,Heckbert SR,Kizer JR.Higher circulating adiponectin levels are associated with increased risk of atrial fibrillation in older adults..Heart2015;101:1368-74 PMCID:PMC5161822

[20] Jung UJ.Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease..Int J Mol Sci2014;15:6184-223 PMCID:PMC4013623

[21] Kizer JR,Arnold AM,Zieman SJ,Tracy RP,Siscovick DS,Ix JH.Total and high-molecular-weight adiponectin and risk of coronary heart disease and ischemic stroke in older adults..J Clin Endocrinol Metab2013;98:255-63 PMCID:PMC3537098

[22] Anan M,Aoki S,Ootani A,Toda S.A promising culture model for analyzing the interaction between adipose tissue and cardiomyocytes..Endocrinology2011;152:1599-605

[23] Colwell JA.Type 2 diabetes, pre-diabetes, and the metabolic syndrome..JAMA2011;306:215